Results 11 to 20 of about 36,204 (201)

Consensus statement on the use of clozapine during the COVID-19 pandemic

Journal of Psychiatry & Neuroscience, 2020
With the ongoing coronavirus disease 2019 (COVID-19) pandemic, psychiatrists find themselves in the clinical situation of being asked by patients, family members and patient advocacy societies to help ensure access to clozapine as a medication critical ...
D. Siskind, W. Honer, Scott Clark, C. Correll, A. Hasan, O. Howes, J. Kane, D. Kelly, Robert Laitman, Jimmy Lee, J. MacCabe, Nickolas Myles, J. Nielsen, P. Schulte, David Taylor, H. Verdoux, A. Wheeler, O. Freudenreich   +17 more
semanticscholar   +1 more source

Clozapine treatment and risk of COVID-19 infection: retrospective cohort study

British Journal of Psychiatry, 2020
Background Clozapine, an antipsychotic with unique efficacy in treatment-resistant psychosis, is associated with increased susceptibility to infection, including pneumonia.
R. Govind, D. Fonseca de Freitas, M. Pritchard, R. Hayes, J. MacCabe   +4 more
semanticscholar   +1 more source

Pharmacokinetic and pharmacodynamic actions of clozapine-N-oxide, clozapine, and compound 21 in DREADD-based chemogenetics in mice

Scientific Reports, 2019
Muscarinic Designer Receptors Exclusively Activated by Designer Drugs (DREADD) gated by clozapine-N-oxide (CNO) allow selective G-protein cascade activation in genetically specified cell-types in vivo.
Martin M Jendryka, M. Palchaudhuri, D. Ursu, Bastiaan van der Veen, B. Liss, D. Kätzel, Wiebke Nissen, A. Pekcec   +7 more
semanticscholar   +1 more source

The DREADD agonist clozapine N-oxide (CNO) is reverse-metabolized to clozapine and produces clozapine-like interoceptive stimulus effects in rats and mice

Scientific Reports, 2018
Clozapine-N-oxide (CNO) has long been the ligand of choice for selectively activating Designer Receptors Exclusively Activated by Designer Drugs (DREADDs).
D. F. Manvich, Kevin A. Webster, S. Foster, M. Farrell, J. Ritchie, J. Porter, D. Weinshenker   +6 more
semanticscholar   +1 more source

Clozapine Combination and Augmentation Strategies in Patients With Schizophrenia -Recommendations From an International Expert Survey Among the Treatment Response and Resistance in Psychosis (TRRIP) Working Group.

Schizophrenia bulletin, 2020
BACKGROUND Evidence for the management of inadequate clinical response to clozapine in treatment-resistant schizophrenia is sparse. Accordingly, an international initiative was undertaken with the aim of developing consensus recommendations for treatment
E. Wagner, J. Kane, C. Correll, O. Howes, D. Siskind, W. Honer, Jimmy Lee, P. Falkai, T. Schneider-Axmann, A. Hasan   +9 more
semanticscholar   +1 more source

Clozapine is strongly associated with the risk of pneumonia and inflammation

General Psychiatry, 2020
Clinicians need to remember that (1) systemic inflammations can increase clozapine level; (2) clozapine, by itself, can cause inflammation, particularly during titration that is too rapid for that patient; (3) clozapine may increase the risk of infection;
J. de Leon, Can-Jun Ruan, H. Verdoux, Chuanyue Wang   +3 more
semanticscholar   +1 more source

Impact of smoking behavior on clozapine blood levels – a systematic review and meta‐analysis

Acta Psychiatrica Scandinavica, 2020
Tobacco smoking significantly impacts clozapine blood levels and has substantial implications on individual efficacy and safety outcomes. By investigating differences in clozapine blood levels in smoking and non‐smoking patients on clozapine, we aim to ...
E. Wagner, Laura McMahon, P. Falkai, A. Hasan, D. Siskind   +4 more
semanticscholar   +1 more source

Do Asian Patients Require Only Half of the Clozapine Dose Prescribed for Caucasians? A Critical Overview

Indian Journal of Psychological Medicine, 2020
Since 1997, studies have found that Asians need lower clozapine doses than Caucasians. Caucasians with average clozapine metabolism may need from 300 to 600 mg/day to reach the therapeutic range (350 ng/ml). Thus, serum clozapine concentration-to-dose (C/
J. de Leon, A. Rajkumar, Arun R Kaithi, G. Schoretsanitis, J. Kane, Chuanyue Wang, Yi-lang Tang, Shih-ku Lin, K. Hong, S. Farooq, C. Ng, Can-Jun Ruan, C. Andrade   +12 more
semanticscholar   +1 more source

Clozapine cessation

European Psychiatry, 2022
IntroductionApproximately 30% of individuals diagnosed with schizophrenia suffer from treatment-resistant or refractory schizophrenia. The gold standard for treatment is clozapine. However, a significant number of patients discontinue clozapine treatment and this carries a poor prognosis.ObjectivesThis study explores patients’ motives for cessation of ...
H. Ktari, A. Ouertani, S. Madouri, A. Aissa, Y. Zgueb, U. Ouali, R. Jomli   +6 more
openaire   +2 more sources

Amino Acid‐Sensing Neurons in the Anterior Piriform Cortex Control Brown Adipose Tissue Thermogenesis

Advanced Science, EarlyView.
This study identifies a class of amino acid‐sensing neurons, APCCRH neurons, which regulate BAT thermogenesis. Leucine deficiency alters intrinsic excitability through GCN2 signaling pathway, activating APCCRH neurons, which in turn regulate BAT thermogenesis via projections to the lateral hypothalamus.
Peixiang Luo, Kexin Tong, Yeting Gan, Min Tang, Yuguo Niu, Kan Liu, Shihong Ni, Shangming Wu, Xiaoxue Jiang, Haizhou Jiang, Fei Xiao, Shanghai Chen, Wei Lv, Xiaoying Li, Feixiang Yuan, Feifan Guo   +15 more
wiley   +1 more source